The operating environment for the pharmaceutical industry is becoming increasingly challenging due to the strong promotion of measures to curb healthcare costs, such as annual NHI drug price revisions.
In order to respond appropriately to these changes in the environment, in fiscal 2021 we transitioned to a holding company structure which is based on three business pillars: the animal health business and the testing and diagnostics business with the pharmaceutical business at the central core., A new medium-term management plan has been formulated with the purpose of enhancing agile decision-making and strengthening governance.
With fiscal 2025 as the final year of the new medium-term management plan, we intend to continue contributing to healthcare by growing into a leading specialty company in our core domestic pharmaceutical business and by creating pharmaceuticals needed by society through the promotion of open innovation.
As a new value provision for realizing total healthcare, the Company will grow its strengths in reproduction, immunochemistry and nutrition in the livestock and fisheries field in the animal health business as well as supporting the health of companion animals.
In the testing and diagnostics business, we will take on the challenge of new business opportunities.
In addition, we will advance overseas business development, mainly in the Asia region,
In addition to strengthening governance under the holding company structure, we will also focus on human resources development to realize our growth strategy, and promote the creation of an environment in which diverse talents can thrive without being limited by age or gender.
We would appreciate your continued understanding and support of our stakeholders.
Takashi Yamaguchi
President, Representative Director
(As of April 1, 2021)